Alzheimer's genetic risk effects on cerebral blood flow across the lifespan are proximal to gene expression.

"Declaration of Competing Interest: All authors declare no conflict of interest with relevance to the current study."

"HLC is funded by a Wellcome Strategic Award [104943/Z/14/Z]. KM is funded by the Wellcome Trust [WT200804]. TML acknowledges funding via a Sêr Cyrmu II Fellowship (East Wales European Regional Development Funds (PNU-80762-CU-14) and the UK Dementia Research Institute at Cardiff University (UK-DRI, which is supported by the Medical Research Council [UKDRI-3003], Alzheimer’s Research UK, and Alzheimer’s Society). We are grateful to all professionals, patients and volunteers involved with the National Centre for Mental Health (NCMH) who took part in our Cardiff study. NCMH is funded by the National Institute for Social Care and Health Research (NISCHR), Welsh Government, Wales (Grant No. BR09). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICOLtd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. CRediT authorship contribution statement: Hannah Chandler: Conceptualization, Methodology, Writing - original draft, Writing - review & editing. Richard Wise: Writing - review & editing, Supervision. David Linden: Writing - review & editing, Supervision, Funding acquisition. Julie Williams: Investigation, Writing - review & editing, Supervision. Kevin Murphy: Investigation, Writing - review & editing, Supervision, Funding acquisition. Thomas Matthew Lancaster: Conceptualization, Methodology, Writing - review & editing, Supervision, Funding acquisition. Disclosure statement: The authors have no conflicts of interests or financial disclosures relevant to this article.: This work was supported by a Ser Cyrmu II Fellowship (European Regional Development Funds: CU149: “Imaging immunity in the genetic risk for Alzheimer’s disease) the Dementia Research Institute (DRI) for supporting this project. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.: We currently have no related papers from this study under submission or submitted for publication.: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf: All authors has reviewed the contents of the manuscript being submitted and approve of its contents and validate the accuracy of the data."